1690O NKT2152, a novel oral HIF-2α inhibitor, in participants (pts) with previously treated advanced clear cell renal carcinoma (accRCC): Preliminary results of a phase I/II study

作者：Eric W. Jonasch, Bradley Alexander McGregor, Pavlos Msaouel, T. Logan, Evan Thomas Hall, M.A. Bilen, Gerald Steven Falchook, B. Shuch, Yousef Zakharia, R. J. Hauke, Michael S. Gordon, A-R. Naqash, Christopher W. Ryan, Ramaprasad Srinivasan, Jim J. Xiao, Weimin Sun, Maricris Esguerra, Gang Lu, Joanne J. Lager, T.K. Choueiri · 发表于：Annals of Oncology · 年份：2024 · DOI：10.1016/j.annonc.2024.08.1783 · 被引用次数：11 · 研究领域：Cancer, Hypoxia, and Metabolism、Renal cell carcinoma treatment、Cancer Research and Treatments